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'Epidemiological research methods
Part Ill. Randomised controlled trials (for interventions)
J. L. BOTHA, D. YACH
Once the magnitude and distribution of a health problem 1,2
and its possible determinants have been established, anempts
to prevent, treat, or control the problem by intervening on one
or more of the determinants should be made. Success should
be evaluated in intervention studies by investigating single
steps in the natural progression of disease (Fig. 1):3 these
present opportunities for primary, secondary or tertiary pre-
vention. In intervention studies the progression from an 'initial'
state to an 'end' state is investigated: a sample of individuals in
either the initial or end state (in more than one group) is
selected, and the groups are compared to evaluate interven-
tions.
Healthy individuals
Diseased
Death/chronic disease/health
Able/disabled individuals
Fig. 1. Simple' model of the natural history of disease showing
levels of prevention.
The randomised controlled trial (RCT) is considered the
most powerful technique for evaluating the effect of interven-
tion. Outcome measurement compares the absolute or relative
difference in outcome between groups that differ due to a
defined intervention. The estimate of this difference can be
biased by any process in the design, execution or analysis of
the RCT which affects the groups differentially.
How the validity of estimated measures of effect can be
affected in RCTs is discussed here.
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What makes an RCT so powerful?
To be able to ascribe to an intervention an observed difference
in outcome between two groups, one subject to that defined
intervention, the two groups should differ with respect to that
intervention only. They should be comparable with respect to
all other variables which may be associated with the interven-
tion and which may also determine the outcome (confounding
variables or confounders4). In an RCT such comparability is
highly likely because of random allocation of individuals to the
two groups. RCTs are considered true scientific experiments,
because the intervention and the allocation of individuals to
groups is under the control of the investigator: allocation is
determined by the study goals and not by patients' needs or
characteristics. For this reason, ethical principles such as full
and informed consent and the right to refuse allocation always
need to be considered.5
RCTs are perhaps best known for assessing drug efficacy
(used here to denote how well the intervention performs in
those who receive the drug; efficacy can only be determined
when 100% compliance can be ensured),6 but they can also be
used to evaluate any treatment programme. 7 As an illustration
we have adapted data from a trial comparing the efficacy of
three interventions: rice water (RW), rice electrolyte solution
(RES) and glucose electrolyte solution (GES) in management
of infantile diarrhoea.8 In a'classic drug trial, patients suffering
from a specified condition amenable to drug therapy are
selected and allocated to two groups, one receiving a new drug
and the other a placebo. Our example differs slightly from this
classic picture in that three groups are compared and there is
no clear control group receiving placebo treatment. As often
happens in intervention studies, it was not ethically justified to·
withhold rehydration from infants with diarrhoea, so the rice-
based solutions were compared with the World Health
Organisation's recommended treatment, 'GES (identified as
the control or standard treatment).
Sampling in RCTs
The target population must be clearly specified before patients
are selected. Sampling from the target population then takes
place in two steps: firstly, selection of a representative sample
from the target population and, secondly, allocation to com-
parable groups.
Specification of the target population is done by defining
inclusion and/or exclusion criteria. In our example, inclusion
criteria were specified as 'infants under the age of 6 months
admined primarily or secondarily with acute gastro-enteritis to
the paediatric wards . . . of a university-based municipal
hospital in Bombay . . . from March 1983 to May 1984'.
Patients requiring intravenous therapy were excluded. Specifi-
cation is done for one of two reasons: to restrict the trial to
patients likely to respond to or to need the intervention, or to
distinguish clearly between a trial of efficacy (does the inter-
vention work under ideal conditions?) and a trial of effective-
ness (does the intervention work under field conditions?).9 If
the target population could be restricted to patients likely to
respond, the difference in response between groups would be
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maximal, and fewer patients would be needed. In a trial of
efficacy, compliance would have to be measured, as efficacy
relates to the disappearance of diarrhoea in those who drink
the rehydration fluid in adequate dosage. Effectiveness relates
to the disappearance of diarrhoea in practice under field
conditions, whether infants drink the rehydration fluid as
prescribed or not and is of importance to clinic administrators.
The specification means that, generalisation (or external
validity) of the results to all infants with diarrhoea (even
within Bombay) is reduced. This reduction is taken to its
extreme in single-patient RCTs. lO,ll
Sample selection is necessary if the specified target popula-
tion is too large. The sampling strategies for descriptive studies2
can be used here as well. The penalties for careless sampling in
an RCT are similar to those in a descriptive study, but it
should be remembered that sample selection is followed by
allocation of sampled individuals to two (or more) groups for
comparison. If too few patients are sampled, the groups will
also have small sample sizes, so that the estimated measure of
effect may lack precision. In addition, negative results may
reflect the small sample size rather than any 'real' lack of
difference between groups. The expected accru~ and drop-out
rates also need to be taken into account when determining
sample size.
Random allocation techniques can make treatment groups
comparable with respect to both known and unknown con-
founding variables. Simple random allocation of N individuals
to two treatment groups, each with N /2 patients, means that
each set of N12 patients within N, have the same probability
of being allocated to either group. 12 With simple random allocation
the probability of obtaining two comparable treatment groups
is high, but there is still a small, but real, probability of the
groups not being comparable.
Comparability in terms of known confounders can be ensured
if patients are randomly allocated to treatment groups within
one (restriction) or several strata (stratification) of known
confounders,12 e.g. infants with mild or severe dehydration
may be allocated to separate treatment groups. If the intake of
patients into the treatment groups occurs over time, one may
wish to ensure that the numbers in the groups remain approxi-
mately equal throughout the intake. This is imponant if there
'is a possibility that intake may be terminated earlier than
planned (funds may run out, for example). Random allocation
may take place in balanced blocks,12 i.e. in such a way that
groups have the same number of patients each (NI2) after
every /I. allocations. Balanced allocation may also be imponant
in multicentre trials to ensure at regular intervals that treatment
groups have the same number of patients from various centres.
A controlled trial with random allocation to treatment groups
is a powerful way of evaluating the effect of interventions, but
several biases can still occur. In particular, because patients
are allocated to different groups, one usually on a new (un-
tested) drug and another on the current accepted treatment,
patients have the right to refuse their allocated treatment. If
the proportions of refusers differ between groups and if those
who refuse differ systematically from those who consent, the
estimate may be biased. Various strategies to handle this have
been proposed. 13 All those who refuse should be followed up
to see if they differ systematically from those who participate
in the trial and to see what influence their omission from or
inclusion in the analysis has. Another strategy is to ensure that
patients do not know whether they are receiving the test drug.
This is sometimes impossible but should always be considered.
In addition to this strategy (single-blind), the person observing
the outcome should where possible be blinded to the interven-
tion, resulting in a double-blind trial. 'Blinding' ensures that
neither the patient nor the investigator can be biased by
knowledge of the treatment received. In our illustration,
patients were allocated to the three groups according to the
day of the week of admission. If admission to hospital is a
random process, allocation would therefore have been random.
Defining the intervention
The intervention being evaluated should be defined clearly
and in enough detail to enable readers to replicate the study on
their own patients. Methods to measure compliance with the
intervention should be described, particularly if the trial is one
of efficacy. In all these trials, two other intervention-related
problems need attention: those of contamination and co-inter-
vention, both of which can result in bias. Contamination
occurs if patients allocated to receive RW actually get GES, or
those allocated to GES actually get RW, wilfully or not. As a
result, the GES and RW groups will not differ absolutely with
regard to the intervention, and its effect will be obscured. The
same applies to contamination between RES and GES.Co-
intervention occurs if there is a departure from the' protocol-
prescribed treatment and some other treatment not used in the
trial, e.g. intravenous rehydration, is introduced. If the co-
intervention occurs in the group on the 'new' treatment,
results may appear better than they really are. On the other
hand, if co-intervention occurs in the other group,. the new
treatment may look less effective than it really is.
Measurement of outcome
In RCTs sampling is prospective, and patients are followed up
until they develop the outcome of interest. Outcomes are
counted as they occur and occurrence or incidence rates are
estimated. The numerator of an incidence rate has been defmed
as the number of longitudinal events reported during a specified
period in a defmed population and the denominator as the
average population at risk during the study period.2 The
denominator should therefore not include those not at risk (i.e.
those who have already suffered the event or are no longer
susceptible). This correction to the denominator need not be
made if the event is rare or the sample size is large, but these
conditions are rarely met in RCTs.
Incidence rates must always be stated in terms of a definite
period of time. If all individuals at risk are observed for the
same length of time, this can easily be done using the midpoint
population at risk as denominator. In RCTs, however, subjects
are often observed for unequal periods of time because people
die, move away or are otherwise lost to follow-up, or they
come under observation after the study has been initiated. To
make full use of the period of observation in each individual, a
person-time unit (e.g. a person-year) is created for the deno-
minator by totalling each person's period of time under
observation.
Comparative measures of effect are of interest in RCTs.
Comparison of rates can be indicated as a rate ratio, indicating
how many times more or less frequently the disease occurs in
one group than in another, or as a rate difference, indicating
the excess rate of occurrence in the group at higher risk or the
decreased rate of occurrence in the group at lower risk. In
Table I these measures are shown as estimates of the incidence
of diarrhoea (5 or more stools per day) on day 7 of the
treatmeIJt programme. The rate ratios are dimensionless,
whereas the rate differences convey the absolute magnitude of
the risk. From both it is clear that the rice-based fluids are
more efficacious in treating diarrhoea than GES.
Random measurement error occurs when measurements are
spread around the true value in each of two groups. If events
are being counted, this means that some non-events have been
counted as events, and some events as non-events. Such a
component of random measurement error will contribute to
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TABLE I. COMPARATIVE MEASURES OF EFFECT IN AN INTERVENTION STUDY
Diarrhoea on day 7 of intervention
Incidence Rate*
rate /1 000 ratio
GES
RW
RES
No.
50
50
50
Incidence
13
1
4
260
20
80
1,00
0,08
0,31
Rate*
difference/1 000
o
240
180
"'Calculated with GES as the baseline.
Rate
difference/1 000
1,00 0 260 1,00 0
0,08 480 20 0,08 240
0,31 360 160 0,62 100
1,00 0 260 1,00 0
0,48 240 20 0,08 140
0,61 180 280 1,08 20
Incidence
rate/1000
520
40
160
460
220
280
TABLE 11. EFFECT OF SYSTEMATIC ERROR IN MEASURING THE OUTCOME
All groups affected Only RES affected
Rate Rate Incidence Rate
ratio difference/1000 rate/1000 ratioIntervention
Diarrhoea incidence in { GES
Table I underestimates RW
real incidence by 50% RES
Diarrhoea incidence in tGES
Table I underestimates RW
real incidence by 10 cases RES
impreCIsIOn of measurement and can be quantified using
confidence limits. 2
Systematic measurement error occurs when measurements
deviate systematically from the true value. If events are being
counted, this means that some non-events have been counted
as events, or some events as non-events, but not both. If such
systematic error occurs in both groups, the comparative esti-
mate may be unbiased, a similar shift in scale occurred in both
groups, so that the difference remains valid. This depends on
which estimate of effect is used. If such systematic error
occurs in one group only, the comparative estimate will always
be biased; a shift in scale occurred in one group only, so that
the difference is not valid. The precision of the estimate is not
affected by systematic error of measurement. These effects are
illustrated in Table 1I, if we assume that some data sheets with
stool counts were mislaid.
The criteria for measuring outcome(s) should be stated in
sufficient detail to permit their application elsewhere, as iden-
tical methods for, and identical application of those methods
will be necessary for the success of other trials. 'Blinding' of
patients and/or observers has already been mentioned. It is
also important to specify beforehand how certain results (par-
ticularly unexpected ones) should be attributed or counted. 14
In addition, all morbidity or mortality should be reported, to
indicate whether the effect is specific to a particular disease or
not.
Analysis
RCTs are examples of prospective studies in that they compare
outcomes in different groups and at different times. In that
sense they are identical to other prospective studies and can be
analysed using survival analysis (e.g. life-table or person-time
techniques).l5 In those, and simpler analyses, the measures of
effect are relative or absolute differences in incidence rates,
which can be biased by confounding variables. Random alloca-
tion as an attempt to control confounding may not always be
successful and the analysis should always investigate this
possibility. 16
In our example, the severity of dehydration may be con-
sidered a confounder, being associated with both the interven-
tion and the outcome. For illustrative purposes mildly and
severely dehydrated infants are analysed separately (Table
Ill), as if 28% of infants receiving GES and 36% of infants
receiving RES had mild dehydration. When all infants were
.analysed together, the greater effect of RES in reducing
diarrhoea in severely dehydrated infants was obscured. .
Applications of intervention studies
Clinical trials, field trials, community trials, before-and-after
studies, and case-control studies are all different types of
intervention studies. In the first four designs listed, prospective
sampling can be used; individuals in the initial state are
sampled and followed up to measure the incidence of the end
state (outcome measurement). The temporal sequence is clear:
intervention precedes outcome. In a case-control study indivi-
duals are sampled in the end state and attempts are then made
to evaluate the intervention they were exposed to. This design
is more commonly used as an analytical study.
1,00
0,13
Rate ratio
4
3
IncidenceNo.
14
18
TABLE Ill. CONFOUNDING EFFECT OF DEHYDRATION STATUS ON THE REDUCTION IN DIARRHOEA INCIDENCE RATE
Mild dehydration Severe dehydration
Incidence Incidence
rate/1000 Rate ratio No. Incidence rate/1000
286 1,00 36 9 250
167 0,58 32 1 31
GES
RES
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Clinical, field and community trials are considered- true
scientific experiments, because the intervention (or allocation
to groups) is under the control of the investigator as allocation
is determined by the study goals and not by patients' needs.
Others are subexperimental designs since intervention is not
under the control of the investigator and may be determined
by the patients' needs. These three trials are all examples of .
controlled trials, in that they have concurrent control groups.
In clinical trials, the subjects are usually patients with disease,
and the intervention aims to prevent sequelae of the initial
disease.8,17-19 These complications may occur with high proba-
bility in a relatively short period of time (as in our example).
In field trials, the subjects are usually individuals who have
not yet become diseased, and the intervention aims at preven-
tion. 20,21 The risk of disease occurring in these subjects is
usually small, therefore more subjects may be needed for a
field trial than for a clinical trial, and disease-free people in the
community have to be visited. Both these factors make field
trials more expensive than clinical trials, usually done at
hospitals. A community trial is an extension of a field trial,
where intervention occurs in a community (not an individual).22
In these studies with a contemporaneous control group, group
comparability is enhanced with respect to confounding variables
related to the passage of time during the study.
In a before-and-after study, a group of individuals is selected
in the initial state and the outcome measured. Intervention
then occurs and the outcome is measured again in the same
individuals, or in a different group from the same community.
Again, the temporal sequence is clear, but other changes may
have taken place with time, decreasing comparability of the
groups. RCTs are regarded as the 'gold standard' for interven-
tion and anal~cal studies. Jot all RCTs are necessarily of
good quality/r25 and neither can RCTs be used in all circum-
stances.26 In the next two articles of the series alternative
subexperimental designs will be discussed.
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Nuus en Kommentaar/News and Comment
Liver transplantation
An excellent review of liver transplantation appeared in the British
Journal of Hospital Medicine (1986; 36: 410). K. E. F. Hobbs and
J. Terblanche (on sabbatical from Cape Town) point out that
during the 3 years since an international consensus conference
held in 1983 there has been an explosive increase in the number of
liver transplant centres throughout the world, with many more
abqur to start. Hobbs and Terblanche estimate that abour 30
patients per million population annually will need a new liver, and
that any patient with untreatable progressive liver or biliary tract
disease should be considered a possible transplant patient, although
some can be excluded immediately because of associated problems
that make the operation impossible.
They point out that the liver must be removed from a brain-
dead donor with an intaer circulation free from replicating hepatitis
and human immunodeficiency virus and with no evidence of
previous liver disease, septicaemia, excessive alcohol intake or a
period of prolonged hypotension or hypoglycaemia. The supply of
donors in the UK is probably sufficient to support the three
transplant units in Cambridge, Birmingham and London, bur as
demand increases this situation will not continue.
Mter discussion of the operation itself and the results, they note
that a significant number of patients world-wide have been restored
to a healthy productive life after liver transplantation and that
children who had a miserable existence with primary biliary
atresia have been greatly helped and are currently surviving into
their fifth year following transplantation. It remains to be seen
how long the grafted livers will continue to function in these
children. Adults have a very good chance of continuing to survive
if they manage to survive the first year after operation. The
longest survival in the world is now 17 years. However, figures for
transplantation for malignancy are more depressing.
The authors say: 'Society must decide how much money it is
prepared to invest in this field. All processes in which the frontiers
of science are being advanced are expensive but the experience
gained can be of value in other spheres and this alone may justify
the investment.'
